(in millions except per share amounts and percentages)
(unaudited)
RECONCILIATION OF GAAP GROSS PROFIT TO NON-GAAP GROSS PROFIT
| Three Months Ended | |||||||
| June 30, | |||||||
| 2021 | 2020 | ||||||
| Gross profit, as reported | $ | 1,007.6 | $ | 798.3 | |||
| Share-based compensation expense | 8.8 | 6.4 | |||||
| COVID-19 shelter-in-place restrictions on manufacturing activities | — | 2.8 | |||||
| Non-GAAP gross profit | $ | 1,016.4 | $ | 807.5 | |||
| Non-GAAP gross profit percentage | 64.8 | % | 61.7 | % | |||
RECONCILIATION OF GAAP RESEARCH AND DEVELOPMENT EXPENSES TO NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES
| Three Months Ended | |||||||
| June 30, | |||||||
| 2021 | 2020 | ||||||
| Research and development expenses, as reported | $ | 238.4 | $ | 198.0 | |||
| Share-based compensation expense | (26.6 | ) | (20.5 | ) | |||
| Acquisition-related | (0.2 | ) | — | ||||
| Non-GAAP research and development expenses | $ | 211.6 | $ | 177.5 | |||
| Non-GAAP research and development expenses as a percentage of net sales | 13.5 | % | 13.6 | % | |||
